Suppr超能文献

百日咳疫苗接种与百日咳:那么现在怎么办?

Pertussis vaccination and whooping cough: and now what?

作者信息

Guiso Nicole

机构信息

Institut Pasteur, Unité de Prévention et Thérapies Moléculaires des Maladies Humaines, 25-28 rue du Dr Roux, F-75015 Paris, France.

出版信息

Expert Rev Vaccines. 2014 Oct;13(10):1163-5. doi: 10.1586/14760584.2014.941816. Epub 2014 Jul 14.

Abstract

Pertussis or whooping cough is a respiratory disease caused by Bordetella pertussis or Bordetella parapertussis that are only known to infect humans. This severe and acute respiratory disease presents epidemic cycles and became a vaccine-preventable disease in the 1940s/1950s when developed countries introduced vaccination. The first type of vaccine developed against this disease was a whole-cell pertussis (wP) vaccine containing inactivated B. pertussis bacteria. Most developed countries produced their own vaccine and given the pediatric nature of the disease at the time of licensure, infants and toddlers were the primary targets and were thus massively vaccinated. The characterization of few virulence factors produced by B. pertussis enabled the development of second-generation pertussis vaccines called the acellular pertussis (aP) vaccines. These only contain 1-5 purified, detoxified B. pertussis proteins and were first introduced in Japan around 30 years ago. Australia, Europe and North America introduced aP vaccines approximately 15 years later, which replaced wP vaccines since then.

摘要

百日咳是一种由百日咳博德特氏菌或副百日咳博德特氏菌引起的呼吸道疾病,这两种细菌仅感染人类。这种严重的急性呼吸道疾病呈现出流行周期,在20世纪40年代/50年代发达国家引入疫苗接种后,它成为了一种可通过疫苗预防的疾病。针对这种疾病研发的第一种疫苗是全细胞百日咳(wP)疫苗,它含有灭活的百日咳博德特氏菌。大多数发达国家自行生产疫苗,鉴于该疾病在获批时具有儿科疾病的特性,婴幼儿是主要接种对象,因此进行了大规模接种。对百日咳博德特氏菌产生的少数毒力因子的特性分析促成了第二代百日咳疫苗即无细胞百日咳(aP)疫苗的研发。这些疫苗仅包含1至5种纯化的、脱毒的百日咳博德特氏菌蛋白质,大约30年前在日本首次推出。大约15年后,澳大利亚、欧洲和北美引入了aP疫苗,自那时起aP疫苗取代了wP疫苗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验